Medical Condition News

RSS

Neurocritical Care Society announces comprehensive set of guidelines on brain aneurysms

The Neurocritical Care Society is releasing a comprehensive set of guidelines this week to guide physicians and hospitals on how to optimally care for patient's ruptured brain aneurysms. One of the strongest recommendations is that all patients receive specialized care at high-volume stroke centers that treat at least 60 cases per year.

20 Sep 2011

ACR launches Simple Tasks campaign to raise awareness on rheumatic diseases

The American College of Rheumatology has launched its Simple Tasks campaign. The initiative aims to raise awareness of the severe impact of rheumatic diseases - such as rheumatoid arthritis, lupus and gout - on the U.S. population and to highlight the importance of rheumatologists in the diagnosis and treatment of these diseases.

20 Sep 2011

UNC researchers develop technique that can observe cellular intricacies of CF

When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.

20 Sep 2011

Calgary researchers discover new class of anti-inflammatory agents

By using a mouse model of inflammation researchers at the University of Calgary have discovered a new class of molecules that can inhibit the recruitment of some white blood cells to sites of inflammation in the body.

20 Sep 2011

OvaGene's new molecular diagnostics laboratory receives CLIA-certification

OvaGene Oncology Inc., a molecular diagnostics company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that the company has received Clinical Laboratory Improvement Act (CLIA) certification for their newly constructed state-of-the-art molecular diagnostics laboratory.

20 Sep 2011

FDA approves Amphastar's ANDA for Enoxaparin Sodium Injection

Watson Pharmaceuticals, Inc. today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 100mg/mL and 150mg/mL strengths.

20 Sep 2011

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

20 Sep 2011

ADHD symptoms might affect adaptive abilities, quality of life for children with ASD

Research supported by the Autism Speaks Autism Treatment Network (ATN), demonstrating that symptoms of attention deficit and hyperactivity worsen quality of life for individuals with autism spectrum disorders (ASD), was presented today at the Society for Developmental & Behavioral Pediatrics Annual Meeting in San Antonio, Texas.

20 Sep 2011

Mayo Clinic, SK biopharmaceuticals collaborate to discover new ALS drugs

South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery of new drugs targeting Amyotrophic Lateral Sclerosis.

20 Sep 2011

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

High dietary salt intake and obesity together trigger abnormal activation of cellular protein

Dietary salt intake and obesity are two important risk factors in the development of high blood pressure. Each packs its own punch, but when combined, they deliver more damage to the heart and kidneys than the sum of their individual contributions.

19 Sep 2011

Laser Med Center receives FDA approval for device to treat Trigeminal Neuralgia

Laser Med Center, which specializes in treating Trigeminal Neuralgia, has received an FDA approval for its revolutionary laser device. This is a non-invasive alternative to surgery, which treats pain through nerve tissue regeneration.

19 Sep 2011

Prevalence of diabetes increases 30% over last four years in urban India

The prevalence of diabetes in urban India is accelerating at a rapid rate and now stands at 5.5 percent (just under 20 million people), compared with 4.6 percent in 2007 - equivalent to a 30 percent increase in actual population numbers over the last four years - according to new research by GfK HealthCare's Roper Global Diabetes Group. Moreover, a full 10 percent of these patients have been diagnosed in the past 12 months.

19 Sep 2011

Scientists discover common genetic variants associated with schizophrenia and bipolar disorder

Common genetic variants contribute to the risk of schizophrenia and bipolar disorder, an international research consortium has discovered.

19 Sep 2011

Amneal announces availability of generic antiepileptic drug, Felbamate

Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.

19 Sep 2011

Boston Scientific introduces Coyote Balloon Catheter for peripheral angioplasty

Boston Scientific Corporation has launched its Coyote Balloon Catheter, a highly deliverable and ultra-low profile 0.014 inch balloon dilatation catheter designed to treat patients undergoing peripheral angioplasty procedures below the knee. The Company has begun marketing the product in the U.S., Europe and other international markets.

19 Sep 2011

Enrollment commences in MINI-AMI study of Impella in STEMI patients

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the first patient enrolled in MINI-AMI, an FDA prospective, randomized, controlled multi-center study to assess the role of 24-hours of direct unloading of the left ventricle with Impella 2.5 support to reduce infarct size in patients with ST-elevation myocardial infarction (STEMI) without cardiogenic shock.

19 Sep 2011

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.

19 Sep 2011

OptiScan's new bedside glucose monitoring system receives European CE Mark

OptiScan Biomedical Corporation, a developer of innovative continuous glucose monitoring systems for use in intensive care units (ICU), today announced that the company's OptiScanner Automatic Bedside Glucose Monitoring System has received CE Mark certification for use in the European Union.

19 Sep 2011

Aestus to develop ATx09-002 for treatment of neuropathic pain

Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357.

19 Sep 2011